Cancer Research UK

FDA authorized the sale of menthol-flavored e-cigarettes – a health policy expert explains how the benefits may outweigh the risks

Retrieved on: 
Wednesday, June 26, 2024
FDA, Marketing, Research, Smoker, Tobacco, Risk, Tobacco industry, Bangladesh Technical Education Board, Menthol, Nicotine, Food, Sale, Conversation, Fruit, Herbal cigarette, Organization, Taste, Health, Truth Initiative, Justice minister, Getty, Cancer Research UK, Smoking, Heated tobacco product, Health policy, Plant, Death, Public, Smoke

The other two are disposable nicotine e-cigarettes – meaning once the prefilled menthol liquid is used, the device cannot be used again.

Key Points: 
  • The other two are disposable nicotine e-cigarettes – meaning once the prefilled menthol liquid is used, the device cannot be used again.
  • The Conversation asked Jamie Hartmann-Boyce, a health policy expert who specializes in tobacco control and e-cigarette products, to explain the pros and cons of the FDA’s authorization and what it could mean for vulnerable populations.

What does the new announcement from the FDA mean?

  • This vapor can be manufactured to include flavors.
  • This is the first time the FDA has authorized marketing of an e-cigarette flavor other than tobacco.
  • “Tobacco flavor” describes a range of flavors that are designed to taste similar to traditional cigarettes.

What are the potential harms, such as risks to kids?

  • Tobacco companies have aggressively marketed menthol cigarettes to Black people.
  • In 2022, the FDA proposed a ban on menthol cigarettes based on their appeal, including to youth, and the potential of such a ban to improve health and prevent deaths.

How are e-cigarettes regulated in the US?

  • For their products to be legally marketed and sold in the U.S., e-cigarette manufacturers must apply for marketing authorization from the FDA.
  • The FDA evaluates these applications based on the scientific evidence provided by the manufacturers.
  • To be approved, the applications must demonstrate that permitting marketing of the products would be appropriate for protection of public health.

Weren’t flavored vapes already available in the US?

  • This is in part because many vaping products available in the U.S. haven’t been authorized for marketing or sale.
  • In addition, some of the products currently available are still being reviewed by the FDA.
  • Meanwhile, the U.S. is awash in sleek, colorful and highly potent vapes manufactured in China.

What are the potential health effects?

Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembrolizumab

Retrieved on: 
Tuesday, June 18, 2024
MSD, Merck & Co., Immunotherapy, CRUK, Antigen presentation, Cancer, Glasgow Royal Infirmary, Cancer Research UK, RECIST, Associate professor, Pembrolizumab, University, Phase, Safety, Progression-free survival, Sponsor, Precision, Merck, Pancreatic cancer, University of Glasgow, PDAC, Surgical oncology, Patient, Therapy, MD, Oncology

GLASGOW, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- The Precision-Panc team at the University of Glasgow, with their Co-Sponsor, NHS Greater Glasgow & Clyde, today announced the opening of the Phase II PRIMUS-006 study evaluating IMM-101, a broad-spectrum immunomodulatory agent containing heat-killed, whole cell Mycobacterium obuense, in combination with gemcitabine and pembrolizumab as first-line treatment in patients with metastatic pancreatic cancer. The PRIMUS-006 study is part of the Precision-Panc Platform master protocol program, which is Co-Sponsored by NHS Greater Glasgow & Clyde and the University of Glasgow and co-ordinated by the Glasgow Oncology Clinical Trials Unit. PRIMUS-006 is endorsed by Cancer Research UK (CRUK Reference: A31505). The study is funded by Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, U.S.A., through its investigator-initiated program with provision of study drug and financial support. The study is also funded by Immodulon Therapeutics Ltd through its investigator-initiated program with provision of study drug and financial support for the study.

Key Points: 
  • PRIMUS-006 is endorsed by Cancer Research UK (CRUK Reference: A31505).
  • The study is also funded by Immodulon Therapeutics Ltd through its investigator-initiated program with provision of study drug and financial support for the study.
  • Key secondary endpoints include safety and tolerability, evaluation of progression-free survival, disease control rate and overall survival.
  • Up to 50 patients with metastatic pancreatic ductal adenocarcinoma will be treated in the study from approximately 15-20 hospital sites in the United Kingdom.

Arialys Therapeutics Appoints Peter Flynn, Ph.D., President and Chief Executive Officer

Retrieved on: 
Tuesday, June 25, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, Neuropsychiatry, Naltrexone/bupropion, University College London, Therapy, Research, FDA, IPSC, Doctor of Philosophy, University, Development, MENA, Merck, IPO, Cancer Research UK, DSM-IV codes, Medicine, CNS, IND, GMP, Biochemistry, Autoimmunity, Trial of the century, Pharmaceutical industry

Arialys Therapeutics , a biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today announced the appointment of Peter Flynn, Ph.D., as President and Chief Executive Officer.

Key Points: 
  • Arialys Therapeutics , a biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today announced the appointment of Peter Flynn, Ph.D., as President and Chief Executive Officer.
  • In conjunction, Jay Lichter, Ph.D., Managing Partner of Avalon BioVentures and former President and CEO of Arialys, has been appointed Chair of the company’s Board of Directors.
  • Prior to Fate, he was Vice President of Research at Ren Pharmaceuticals.
  • Dr. Flynn started his industry career at the antibody therapeutics company KaloBios, where as head of biochemistry he helped build both the platform technology and therapeutic pipeline.

Epstein-Barr virus: how does a common infection trick the immune system into attacking the brain in people with MS?

Retrieved on: 
Tuesday, June 18, 2024
Protein, Epstein–Barr virus infection, Antibody, Brain, VCA, Infectious mononucleosis, Cancer Research UK, Research, Autoimmune disease, Conditional sentence, Genetics, University, Immunity, Risk, Cell, Life, Central nervous system, EBV, Immune system, Epstein–Barr virus, Traffic barrier, Multiple sclerosis, Viral, Molecular mimicry, Virus, Patient, Disease, Bacteria, Infection, Interleukin, Blood Cancer UK, EBNA1, Vaccine

Almost 3 million people worldwide have multiple sclerosis (MS) – an autoimmune disease caused by the immune system mistakenly attacking the brain and central nervous system.

Key Points: 
  • Almost 3 million people worldwide have multiple sclerosis (MS) – an autoimmune disease caused by the immune system mistakenly attacking the brain and central nervous system.
  • This is largely because researchers still don’t fully understand what goes wrong in the immune system to cause MS.
  • But our latest research has revealed new insights into the way certain immune cells behave in people with MS.
  • Although the causes of MS aren’t fully understood, we know that genetics, lifestyle and environment factors can all influence MS risk.
  • But how does EBV cause MS – and why does a common virus only cause MS in a few people?

Altered immunity

Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis

Retrieved on: 
Thursday, May 30, 2024
Genomics, Proteomics, Human genetics, University, Risk, Kingdom of Poland, Nature Communications, Protein, Disease, Blood, Cancer, Research, Genetics, The Road Ahead, Cancer Research UK, Cancer Epidemiology Unit

They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis.

Key Points: 
  • They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis.
  • "To save more lives from cancer, we need to better understand what happens at the earliest stages of the disease.
  • Data from thousands of people with cancer has revealed really exciting insights into how the proteins in our blood can affect our risk of cancer.
  • Understanding the specific role these proteins play in cancer development and identifying the most reliable ones for testing are crucial next steps.

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Retrieved on: 
Monday, March 25, 2024
Research, Cancer Research UK, Biochemistry, Drug design, Partnership, Physician, Patient, SAN, MYCN, University, Cancer, Inflammation, TPD, Doctor of Philosophy, Therapy, Molecular biology, ALK, Pediatrics

SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that it is part of a diverse research team of international experts selected as awardees in this year’s Cancer Grand Challenges competition. The team includes scientists, physicians and patient advocacy groups from 10 institutions in the United States, the United Kingdom, France, Germany and Austria and will be led by Yael Mossé, M.D., Professor of Pediatrics and Patricia Brophy Endowed Chair in Neuroblastoma Research at the Children’s Hospital of Philadelphia, and Martin Eilers, Ph.D., Professor of Biochemistry and Molecular Biology at the University of Würzburg, Germany.

Key Points: 
  • The project entitled “Knocking Out Oncogenic Drivers and Curing Childhood Cancers” (KOODAC) has the goal of developing orally bioavailable targeted protein degraders that have the potential to dramatically improve cure rates for children affected by solid tumors.
  • "Team KOODAC brings together an interdisciplinary, international team of scientific experts, all sharing the vision of developing safe and effective drugs against previously undruggable childhood cancers," said Dr. Mossé.
  • This year, five teams were selected to receive funding of up to £20 million (approximately $25 million) over a period of five years.
  • The funds, which will support only the academic groups involved in the project, will be managed by Team KOODAC.

Global Leaders in Cancer Research and Biotech Join The Mark Foundation for Cancer Research's Scientific Advisory and Industry Advisory Committees

Retrieved on: 
Tuesday, April 2, 2024
Molecule, Medicine, Cancer Research UK, FRS, Weill Cornell Medicine, Francis Crick Institute, B cell, Patient, Investment, Children's National Hospital, Therapy, Research, Biotechnology, Genentech, Dana–Farber Cancer Institute, Committee, Trial of the century, University, University College Hospital, Metastasis, Multiple sclerosis, Drug discovery, MBBS, Chairperson, MD, University College London, Senior, FRCP, University of California, Berkeley, Hospital, Nationwide Children's Hospital, Marker beacon, Diagnosis, Lung cancer, Ludwig Cancer Research, University of Pennsylvania, Doctor of Philosophy, BTK, GV (company), Celera Corporation, Pharmaceutical industry

NEW YORK, April 2, 2024 /PRNewswire/ -- The Mark Foundation for Cancer Research, a leading nonprofit dedicated to advancing research that transforms the prevention, diagnosis, and treatment of cancer, proudly announces the appointment of new members to its Scientific Advisory and Industry Advisory Committees.

Key Points: 
  • The committee assists the foundation in reviewing its scientific goals and grant applications, as well as providing strategic advice and support for its research programs and investments.
  • "The outstanding researchers on our advisory committees provide invaluable guidance and insight to help steer its programs toward success and impact."
  • "The Mark Foundation's funding of high-risk, high-impact research is essential in the quest to achieve real breakthroughs in cancer research," said Johanna Joyce, PhD.
  • "I am honored to join the Scientific Advisory Committee, to support the next generations of scientists and projects that will revolutionize treatments for patients."

Cancer Grand Challenges announces five new teams taking on cancer’s toughest challenges

Retrieved on: 
Wednesday, March 6, 2024
Research, Philanthropy, Fund Raising, General Health, Health, Foundation, Other Philanthropy, Science, Oncology, Other Science, Allergy, Massachusetts Institute of Technology, Incidence, Radiation, KITZ, NCI, PROTECT, Interdisciplinarity, Cancer Research UK, Prostate, Geography, National Cancer Institute, Breast, Neoplasm, Autoimmunity, University, KiKa, Death, Antigen, Patient, Factorization of polynomials, Disease, Massachusetts General Hospital, Grand Challenges, Risk, Mortality, Morehouse School of Medicine, Infection, Pharmaceutical industry

Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges: cancer inequities, early-onset cancers, solid tumors in children and T-cell receptors.

Key Points: 
  • Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges: cancer inequities, early-onset cancers, solid tumors in children and T-cell receptors.
  • These include the Scientific Foundation of the Spanish Association Against Cancer, the Bowelbabe Fund for Cancer Research UK, Institut National Du Cancer, the Dutch Cancer Society, The Mark Foundation for Cancer Research and KiKa (Children Cancer Free Foundation).
  • “Together with our network of visionary partners and research leaders, Cancer Grand Challenges unites the world's brightest minds across boundaries and disciplines and aims to overcome cancer’s toughest problems,” said Dr. David Scott, Director of Cancer Grand Challenges.
  • The Cancer Grand Challenges community has grown to more than 1,200 investigators and collaborators with 16 teams from across the world taking on 13 challenges.

Team SAMBAI, TOUCH, The Black Breast Cancer Alliance, Named As Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024
Research, Women, Communications, African American, Health, Social Activism, Consumer, Science, Oncology, Breast cancer, Pancreatic Cancer Action, Incidence, Prostate Cancer UK, Survivor, BSN, Caregiver, Doctor of Philosophy, Prostate cancer, RN, MD, Education, Cancer Research UK, Prostate, National Cancer Institute, Breast, Safety, Organization, Patient, Ecosystem, Clinical trial, Factorization of polynomials, Team, Grand Challenges, Trust, Pancreatic cancer, Mortality, Morehouse School of Medicine, Cancer, Partnership, Pharmaceutical industry

Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges.

Key Points: 
  • Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges.
  • TOUCH, The Black Breast Cancer Alliance, as part of Team SAMBAI, is the first U.S.
  • Black-led breast cancer advocacy group to be an integral partner in the international Cancer Grand Challenge study.
  • Inequities in cancer prevention, screening, and treatment lead to disparities in cancer incidence and mortality and are a significant public health concern.

Team SAMBAI, Yemaachi Biotech, Named as Recipient of Prestigious Cancer Grand Challenges Award

Retrieved on: 
Wednesday, March 6, 2024
Science, Biotechnology, Research, Oncology, Health, Data Management, Technology, Genetics, Incidence, Doctor of Philosophy, Cancer Research UK, Prostate, National Cancer Institute, Breast, Biobank, Medicine, Patient, Factorization of polynomials, Genomics, Health equity, Diagnosis, Mortality, Cancer, Pharmaceutical industry

Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.

Key Points: 
  • Yemaachi today announced that a global, interdisciplinary team of researchers, including Yemaachi CEO & Co-founder Yaw Bediako, has been named a recipient of a Cancer Grand Challenges award of up to $25 million over five years to advance research on cancer inequities.
  • “We are confident that this work will be fruitful and will contribute to innovations that will benefit patients globally.
  • We are honored by Team SAMBAI’s belief in our scientific work and impact-driven mission.”
    Inequities in cancer prevention, screening, diagnosis, treatment, and research lead to disparities in cancer incidence and mortality and are a major public health concern.
  • Cancer Grand Challenges is a global funding initiative, co-founded by Cancer Research UK and the National Cancer Institute in the US, that supports a community of diverse, global teams to come together, think differently and take on cancer’s toughest challenges.